COVID-19 Vaccination Associated With Reduced Postoperative SARS-CoV-2 Infection and MorbidityObservational Study Published on 2022-01-012022-10-05 Journal: Annals of surgery [Category] 임상, [키워드] 30-Day mortality Affair benefit Complication complications Confidence intervals controls COVID-19 COVID-19 infection COVID-19 vaccination detect determine Endpoint event hospital inclusion criteria individual Moderna morbidity Mortality Observational cohort study Patient Pfizer positive postoperative Prevent pulmonary complication Rate Ratio readmission SARS-CoV-2 second dose secondary significant difference tested The United States thrombotic complication Thrombotic complications vaccination Vaccine Vaccines veteran while [DOI] 10.1097/SLA.0000000000005176 PMC 바로가기 [Article Type] Observational Study
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?ocrelizumab 치료 MS 환자에서 SARS-CoV-2 백신 접종 후 세로 체액 반응: 기다렸다가 다시 채우려면?Article Published on 2022-01-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, 치료기술, [키워드] antibodies B-cell B-cells baseline booster vaccination COVID-19 cut-off detectable disease first vaccination humoral Humoral response humoral responses infusion longitudinal Moderna mRNA mRNA-1273 Multiple multiple sclerosis occurred Ocrelizumab Patient patients patients treated SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 vaccination Seroconversion therapy treated treated patient vaccination were measured [DOI] 10.1016/j.msard.2021.103416 PMC 바로가기 [Article Type] Article
COVID-19 Vaccination for Frail Older Adults in Singapore – Rapid Evidence Summary and Delphi Consensus Statements싱가포르의 허약한 노인을 위한 COVID-19 예방 접종 - 신속한 증거 요약 및 델파이 합의 선언문Article Published on 2022-01-012022-09-11 Journal: The Journal of Frailty & Aging [Category] 임상, [키워드] administration Adults adverse event article clinical trials conducted Consensus content controlled trials COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines DelPhi dose Effectiveness Efficacy Efficacy and safety elderly elicit Evidence frail Future Geriatrician Google Scholar hand include Life expectancy Moderna Older older adult Older adults participant Patient Pfizer-BioNTech phase Randomized Randomized controlled trials Rapid recommendation reference reported Serious Adverse Events Singapore thought Trial vaccination Vaccine vaccine efficacy Vaccines Web of Science [DOI] 10.14283/jfa.2022.12 PMC 바로가기 [Article Type] Article
Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers노출되고 순진한 의료 종사자 집단에서 COVID-19 mRNA 백신에 대한 초기 항체 반응의 결정 요인Clinical Trial Published on 2022-01-012022-09-11 Journal: EBioMedicine [Category] 변종, 임상, 진단, 치료기술, 치료법, [키워드] 95% CI Adults adverse events Affect allergy Alpha Analysis analyzed antibody Antibody avidity antibody levels Antibody Response Antigen antigens avidity Barcelona Beta BNT162b2 brand center Cohort Comorbidities Comorbidity COVID-19 COVID-19 mRNA vaccine Daniel Data collection days post-infection decision determinant development dose Effectiveness Efficacy European evaluated expected Factor Gamma had no Health care Health care worker health care workers healthcare worker healthy individual heterogeneity IgA IgG IgG and IgM IgG level IgG levels Immunity indicate Infectious disease Infectious diseases Influenza Innovation maintenance manuscript Moderna mRNA mRNA vaccination mRNA vaccines mRNA-1273 naïve neutralization neutralization capacity neutralizing capacity nucleocapsid omicron Pfizer/BioNTech preparation Program reagent receiving recommendation respond response responsiveness robust SARS-CoV-2 SARS-CoV-2 spike Science second dose seropositive Severo Ochoa shown Single-dose smoking Spanish state Study design Support supported symptomatic systemic adverse effect systemic adverse effects technology the preparation union vaccination vaccine doses vaccinees variant variants variants of concern wild-type [DOI] 10.1016/j.ebiom.2021.103805 PMC 바로가기 [Article Type] Clinical Trial
COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus리툭시맙으로 치료 중인 환자의 코로나 백신 접종: 이란의 2건 사례 발표 및 천포창에 특정 초점을 맞춘 최신 지식 검토Review Published on 2022-01-012022-09-12 Journal: Dermatologic therapy [Category] SARS, 진단, [키워드] administration approach approved AstraZeneca Bharat Clinicians country COVID COVID-19 COVID-19 vaccine described disease disorder Google Scholar Immunomodulatory agent Iran knowledge Moderna multiple sclerosis Organ failure Patient Pfizer protocol raised receiving recommendation rheumatologic disorders risk single dose Sputnik. the timing Treatment vaccination Vaccine [DOI] 10.1111/dth.15216 PMC 바로가기 [Article Type] Review
B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control studyB 세포 고갈자는 다발성 경화증 환자에서 SARS-CoV-2 백신에 대한 체액 반응을 약화: 사례 대조 연구Article Published on 2022-01-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, 치료기술, [키워드] 95% CI absolute levels addition adjusted age ANCOVA antibody Antibody Response Antibody testing antigens approved attenuate attenuation B-cell case-control study center Comprehensive continuous variable covariate covariates COVID-19 COVID-19 infection depleting determine disease Disease modifying therapies dose enrolled FDA Final group humoral Humoral response Johnson & Johnson Johnson & Johnson Labcorp levels of antibody logistic regression models lymphocyte Lymphocyte count Moderna multiple sclerosis not differ Ocrelizumab Ofatumumab outcome p-values P-values <0.05 Patient patients treated Pfizer-BioNTech Quantitative raised recruited Research SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines semi-quantitative Sex shown sphingosine Spike protein tested the antibody response the SARS-CoV-2 the vaccine Therapies therapy Treatment Vaccine was tested [DOI] 10.1016/j.msard.2021.103413 PMC 바로가기 [Article Type] Article
Innovations and development of Covid-19 vaccines: A patent reviewReview article Published on 2022-01-012022-10-05 Journal: Journal of infection and public health [Category] SARS, 신약개발, [키워드] Bacteria confirmed case country COVID-19 COVID-19 vaccine COVID-19 vaccines development DNA domain effective Innovation janssen Moderna Patent Protein subunit provide reported rising RNA SARS-CoV-2 viral spike (S) protein trials Vaccine Vaccines viral receptor-binding domain virus was done [DOI] 10.1016/j.jiph.2021.10.021 [Article Type] Review article
mRNA vaccines against COVID-19: a showcase for the importance of microbial biotechnologyCOVID-19에 대한 mRNA 백신: 미생물 생명공학의 중요성에 대한 쇼케이스Article Published on 2022-01-012022-09-11 Journal: Microbial Biotechnology [Category] SARS, 변종, [키워드] Adverse reaction Adverse reactions Alpha Beta variant booster chills Coverage COVID-19 CureVac delta variant Delta variants Efficacy Extensive Facial nerve facial nerve paralysis fatigue Fever Formulation group headache increase in Infection injection injection site pain lipid composition male microbial Mild Moderna mRNA mRNA vaccine mRNA vaccines muscle pain myocarditis nanoparticle nerve paralysis neutralization observational studies observational study Older Pain Pfizer-BioNTech phase Population pseudouridine replacement risk safety profile SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 spike protein severe COVID-19 Spike protein subject Surveillance symptomatic disease the SARS-CoV-2 uridine Vaccine vaccine trial variant viruses [DOI] 10.1111/1751-7915.13974 PMC 바로가기 [Article Type] Article
Reduced Humoral Response of SARS-CoV-2 Antibodies following Vaccination in Patients with Inflammatory Rheumatic Diseases—An Interim Report from a Danish Prospective Cohort StudyCommunication Published on 2021-12-282022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% confidence interval Administered age Antibody Response Antibody test baseline biologic Bloods BNT162b2 vaccine Booster vaccine Cambridge Clinical data collected Combination combination therapy COVID-19 pandemic COVID-19 vaccine cut-off defined detection determine disease Disease activity drug Efficacy Gender Germany Healthcare provider Humoral response IgG IgG level IgG response immune response Immunoglobulin information Interim Mainz median medians Moderna mRNA-1273 vaccine Musculoskeletal National Outpatient Patient patient reported outcome patients treated Pfizer Prospective prospective cohort study psoriatic arthritis receiving report reported response Result rheumatoid arthritis risk RMD SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 vaccination SARS-CoV-2 vaccine significant increase significantly higher significantly lower study population tested the median the SARS-CoV-2 Thermofisher treated Treatment USA vaccination Vaccine was measured was used were used [DOI] 10.3390/vaccines10010035 PMC 바로가기 [Article Type] Communication
Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccinationArticle Published on 2021-12-272022-10-04 Journal: Scientific Reports [Category] SARS, 치료기술, [키워드] All participant antibody antibody concentration Antibody testing Cohort Concentration COVID-19 COVID-19 mRNA Vaccination COVID-19 mRNA vaccine COVID-19 vaccination detectable detection dose effective ELISA enrolled enzyme-linked immunosorbent Epidemiology first vaccination Infectious diseases invasive less Moderna mucosal nasal no significant difference oral participant Pfizer/BioNTech provided Research SARS-CoV-2 IgG SARS-CoV-2 IgG antibody second vaccination serum antibody specimen subset upper respiratory tract vaccination Vaccine Vaccines viral infection [DOI] 10.1038/s41598-021-03931-3 PMC 바로가기 [Article Type] Article